XML 47 R37.htm IDEA: XBRL DOCUMENT
v3.21.2

Asset Retirement Obligations (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended
--- | --- | --- | ---
Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020
Asset Retirement Obligation Disclosure [Abstract] |  |  |  |  |  |
Proceeds from Sale of Productive Assets | $ 160,400 | [1] |  |  | $ 0 | $ 160,385
Gain on sale of non-financial assets | 132,800 |  | $ 0 | $ 132,818 | 0 | 132,818
TerSera Maximum Development, Regulatory and Commercial Milestones |  |  |  |  |  | 65,000
Xermelo Pretax Net Loss |  |  |  | (2,100) |  | (12,100)
Severance Costs |  |  |  |  |  | 5,500
Debt Instrument [Line Items] |  |  |  |  |  |
Severance Costs |  |  |  |  |  | 5,500
Proceeds from Sale of Productive Assets | 160,400 | [1] |  |  | 0 | 160,385
Gain on sale of non-financial assets | $ 132,800 |  | $ 0 | 132,818 | $ 0 | 132,818
TerSera Maximum Development, Regulatory and Commercial Milestones |  |  |  |  |  | 65,000
Xermelo Pretax Net Loss |  |  |  | $ (2,100) |  | (12,100)
R&D severance costs [Member] |  |  |  |  |  |
Asset Retirement Obligation Disclosure [Abstract] |  |  |  |  |  |
Severance Costs |  |  |  |  |  | 2,500
Debt Instrument [Line Items] |  |  |  |  |  |
Severance Costs |  |  |  |  |  | 2,500
SG&A severance costs [Member] |  |  |  |  |  |
Asset Retirement Obligation Disclosure [Abstract] |  |  |  |  |  |
Severance Costs |  |  |  |  |  | 3,000
Debt Instrument [Line Items] |  |  |  |  |  |
Severance Costs |  |  |  |  |  | $ 3,000
[1] | 10. Asset Sale In September 2020, the Company completed the sale of XERMELO® and related assets to TerSera. The upfront consideration paid by TerSera, subject to a working capital adjustment as set forth in the Asset Purchase and Sale Agreement, was $160.4 million and the net gain recognized in connection with the XERMELO sale was $132.8 million. The gain is reflected on the condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September 30, 2020. The Company remains eligible to receive development, regulatory and sales milestone payments of up to an aggregate of $65 million for the development and commercialization of telotristat ethyl in patients with biliary tract cancer and mid-teens royalty payments on net sales of XERMELO in biliary tract cancer. The Company has determined that these amounts are constrained until the achievement, if any, of specific events. If or when the constraint is determined to be resolved, the Company will re-evaluate the overall gain in connection with the XERMELO sale and recognize an adjustment on a cumulative catch-up basis in the period that the determination is made. The XERMELO sale did not meet the criteria for reporting discontinued operations as there was not a strategic shift that has (or will have) a major effect on the Company’s operations. For the three and nine months ended September 30, 2020, the pretax net loss on the condensed consolidated statement of comprehensive income (loss) for the Company’s XERMELO operations is $2.1 million and $12.1 million, respectively. As a result of the XERMELO sale, the Company implemented a reduction in force which reduced its workforce by approximately fifty percent. The Company incurred and recognized severance charges of approximately $5.5 million through September 30, 2020. Of this charge, $2.5 million was recorded in research and development expense and $3.0 million was recorded in selling, general and administrative expense in the accompanying condensed consolidated statement of comprehensive income (loss) for the three and nine months ended September 30, 2020.

X
- Definition Gain on sale of non-financial assets + References No definition available. + Details
Name: | lxrx_GainOnSaleOfNonFinancialAssets
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition TerSera Maximum Development, Regulatory and Commercial Milestones + References No definition available. + Details
Name: | lxrx_TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Xermelo Pretax Net Loss + References No definition available. + Details
Name: | lxrx_XermeloPretaxNetLoss
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_AssetRetirementObligationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DebtInstrumentLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromSaleOfProductiveAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585 + Details
Name: | us-gaap_SeveranceCosts1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_RestructuringCostAndReserveAxis=lxrx_RDSeveranceCostsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RestructuringCostAndReserveAxis=lxrx_SGASeveranceCostsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |